Advertisement


Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease

2015 IASLC World Conference on Lung Cancer

Advertisement

Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or docetaxel (Abstracts ORAL 31.01, 31.02, and 31.03).



Related Videos

Lung Cancer

Christine D. Berg, MD, on Screening for Lung Cancer in Those at High Risk

Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).

Lung Cancer

Nagashree Seetharamu, MD, on Anti-Glycan Antibody Profiling in De Novo Stage IV Non Small Cell Lung Cancer

Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).

Lung Cancer

Everett E. Vokes, MD, on Controversies in Stage IIIA Disease

Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality choices; and using induction chemotherapy (Abstract ED10).

Lung Cancer

Jennifer King, PhD: Scientific Perspectives From the Lung Cancer Alliance

Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.

Lung Cancer

Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC

Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of sensitivity to afatinib or neratinib (Abstracts ORAL 3.01, 3.02, and 3.03).

Advertisement

Advertisement




Advertisement